{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:35:15Z","timestamp":1783629315166,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P210006-B11"],"award-info":[{"award-number":["P210006-B11"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W1232-B11"],"award-info":[{"award-number":["W1232-B11"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejphar.2020.173818","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T03:53:58Z","timestamp":1608263638000},"page":"173818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The bradycardic agent ivabradine decreases conduction velocity in the AV node and in the ventricles in-vivo"],"prefix":"10.1016","volume":"893","author":[{"given":"Daniel","family":"Amstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-5825","authenticated-orcid":false,"given":"Florian","family":"Badt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Rubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald E.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Uhrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3033-0874","authenticated-orcid":false,"given":"Karlheinz","family":"Hilber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-4966","authenticated-orcid":false,"given":"Xaver","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Todt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173818_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/imj.13093","article-title":"Inappropriate sinus tachycardia: focus on ivabradine","volume":"46","author":"Abed","year":"2016","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ejphar.2020.173818_bib2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jce.12081","article-title":"Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia","volume":"24","author":"Al-Ghamdi","year":"2013","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.ejphar.2020.173818_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCEP.111.963561","article-title":"Intraventricular conduction delay in a standard 12-lead electrocardiogram as a predictor of mortality in the general population","volume":"4","author":"Aro","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1073\/pnas.1010122108","article-title":"Deep bradycardia and heart block caused by inducible cardiac-specific knockout of the pacemaker channel gene Hcn4","volume":"108","author":"Baruscotti","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2020.173818_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cvr\/cvs299","article-title":"Early repolarization in mice causes overestimation of ventricular activation time by the QRS duration","volume":"97","author":"Boukens","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2020.173818_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cvr\/cvs299","article-title":"Early repolarization in mice causes overestimation of ventricular activation time by the QRS duration","volume":"97","author":"Boukens","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2020.173818_bib8","first-page":"7512318","article-title":"The effect of ivabradine on the human atrial myocardial contractility in an in vitro study","author":"Chaban","year":"2019","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.ejphar.2020.173818_bib9","doi-asserted-by":"crossref","first-page":"H372","DOI":"10.1152\/ajpheart.01091.2001","article-title":"Correlation of repolarization of ventricular monophasic action potential with ECG in the murine heart","volume":"283","author":"Danik","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ejphar.2020.173818_bib11","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1113\/jphysiol.2013.253765","article-title":"Funny channel gene mutations associated with arrhythmias","volume":"591","author":"DiFrancesco","year":"2013","journal-title":"J. Physiol"},{"key":"10.1016\/j.ejphar.2020.173818_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15420\/aer.2015.4.1.9","article-title":"HCN4, sinus bradycardia and atrial fibrillation","volume":"4","author":"DiFrancesco","year":"2015","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"10.1016\/j.ejphar.2020.173818_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2012.00006","article-title":"Cardiac safety implications of hNav1.5 blockade and a framework for pre-clinical evaluation","volume":"3","author":"Erdemli","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/pace.13478","article-title":"Ivabradine use as an antiarrhythmic therapy in congenital junctional ectopic tachycardias","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.recesp.2019.06.006","article-title":"Ivabradine for chronic heart rate control in persistent atrial fibrillation","volume":"73","author":"Fontenla","year":"2020","journal-title":"Design of the BRAKE-AF project. Rev. Esp. Cardiol. (Engl. Ed)"},{"key":"10.1016\/j.ejphar.2020.173818_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173818_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173818_bib19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173818_bib20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/eurheartj\/ehl176","volume":"27","author":"Fuster","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2020.173818_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.33594\/000000119","article-title":"Pharmacological profile of the bradycardic agent ivabradine on human cardiac ion channels","volume":"53","author":"Haechl","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2020.173818_bib22","first-page":"1842","article-title":"Sex and race differences in QRS duration","volume":"18","author":"Hnatkova","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.ejphar.2020.173818_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1152\/physrev.00007.2016","article-title":"Murine electrophysiological models of cardiac arrhythmogenesis","volume":"97","author":"Huang","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2020.173818_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.hrcr.2019.03.007","article-title":"Ivabradine for treatment of tachyarrhythmias in children and young adults","volume":"5","author":"Janson","year":"2019","journal-title":"HeartRhythm. Case. Rep."},{"key":"10.1016\/j.ejphar.2020.173818_bib25","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173818_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020300","article-title":"Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart","volume":"6","author":"Koenig","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173818_bib27","doi-asserted-by":"crossref","first-page":"H564","DOI":"10.1152\/ajpheart.00441.2013","article-title":"Enhanced currents through L-type calcium channels in cardiomyocytes disturb the electrophysiology of the dystrophic heart","volume":"306","author":"Koenig","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejphar.2011.07.025","article-title":"Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions","volume":"668","author":"Koncz","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib29","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2014.10.062","article-title":"Ivabradine for rate control in atrial fibrillation","volume":"179","author":"Kosiuk","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1476-5381.1988.tb11499.x","article-title":"Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs","volume":"94","author":"Krumpl","year":"1988","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ihj.2017.09.007","article-title":"Ivabradine for junctional ectopic tachycardia in post congenital heart surgery","volume":"69","author":"Kumar","year":"2017","journal-title":"Indian Heart J."},{"key":"10.1016\/j.ejphar.2020.173818_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/2150135119876600","article-title":"Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: a preliminary study","volume":"10","author":"Kumar","year":"2019","journal-title":"World J. Pediatr. Congenit. Heart Surg."},{"key":"10.1016\/j.ejphar.2020.173818_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1152\/physiolgenomics.00161.2005","article-title":"Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle","volume":"24","author":"Leoni","year":"2005","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.ejphar.2020.173818_bib35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41467-019-14039-8","article-title":"Impaired neuronal sodium channels cause intranodal conduction failure and reentrant arrhythmias in human sinoatrial node","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2020.173818_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S1734-1140(13)71500-7","article-title":"Ivabradine (a hyperpolarization activated cyclic nucleotide-gated channel blocker) elevates the threshold for maximal electroshock-induced tonic seizures in mice","volume":"65","author":"Luszczki","year":"2013","journal-title":"Pharmacol. Rep."},{"issue":"Suppl. l","key":"10.1016\/j.ejphar.2020.173818_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0022-0736(94)80039-1","article-title":"Effects of age, sex, and race on ECG interval measurements","volume":"27","author":"Macfarlane","year":"1994","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jelectrocard.2010.05.015","article-title":"In vivo studies of Scn5a+\/- mice modeling Brugada syndrome demonstrate both conduction and repolarization abnormalities","volume":"43","author":"Martin","year":"2010","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib39","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2020.173818_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12872-017-0540-3","article-title":"Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials","volume":"17","author":"Mengesha","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ejphar.2020.173818_bib41","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/pace.13480","article-title":"Beneficial effects of ivabradine in atrial or ventricular arrhythmias","volume":"41","author":"Mert","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib42","doi-asserted-by":"crossref","first-page":"H435","DOI":"10.1152\/ajpheart.00591.2008","article-title":"Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure","volume":"296","author":"Milliez","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib43","first-page":"H747","article-title":"Measurement of heart rate and Q-T interval in the conscious mouse","volume":"274","author":"Mitchell","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2014.04.183","article-title":"Might ivabradine be useful in permanent atrial fibrillation?","volume":"175","author":"Moubarak","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4149\/gpb_2018046","article-title":"Ivabradine reduces baseline and stress-induced increase of heart rate and blood pressure and modulates neuroendocrine stress response in rats depending on stressor intensity","volume":"38","author":"Ondicova","year":"2019","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.ejphar.2020.173818_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1995.tb15002.x","article-title":"Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on Guinea-pig isolated cardiac preparations","volume":"115","author":"Perez","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.RES.83.4.431","article-title":"Lidocaine action on Na+ currents in ventricular myocytes from the epicardial border zone of the infarcted heart","volume":"83","author":"Pu","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2020.173818_bib48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1159\/000430278","article-title":"Proper voltage-dependent ion channel function in dysferlin-deficient cardiomyocytes","volume":"36","author":"Rubi","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2020.173818_bib49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/00207450600808669","article-title":"On the mechanism of carbamazepine-induced antinociception in the formalin test","volume":"116","author":"Sahebgharani","year":"2006","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173818_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000095430","article-title":"Novel if current inhibitor ivabradine: safety considerations","volume":"43","author":"Savelieva","year":"2006","journal-title":"Adv. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib51","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s11064-016-2136-1","article-title":"Influence of ivabradine on the anticonvulsant action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice","volume":"42","author":"Sawicka","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2020.173818_bib52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/mol.105.020701","article-title":"Bradycardic and proarrhythmic properties of sinus node inhibitors","volume":"69","author":"Stieber","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173818_bib54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanboga","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib55","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.84.4.1831","article-title":"The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2020.173818_bib56","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/jimd.12264","article-title":"Oral batyl alcohol supplementation rescues decreased cardiac conduction in ether phospholipid-deficient mice","volume":"43","author":"Todt","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejphar.2020.173818_bib57","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib58","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.hrthm.2014.08.007","article-title":"If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation","volume":"11","author":"Verrier","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ejphar.2020.173818_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jce.12569","article-title":"Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation","volume":"26","author":"Verrier","year":"2015","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib60","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/EP087964","article-title":"Increased sarcoplasmic\/endoplasmic reticulum calcium ATPase 2a activity underlies the mechanism of the positive inotropic effect of ivabradine","volume":"105","author":"Xie","year":"2020","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.ejphar.2020.173818_bib61","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.pain.2014.05.021","article-title":"Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels","volume":"155","author":"Young","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2020.173818_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchromb.2013.01.016","article-title":"A validated, rapid UPLC-MS\/MS method for simultaneous ivabradine, reboxetine, and metoprolol analysis in human plasma and its application to clinical trial samples","volume":"927","author":"Zoerner","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920309237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920309237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:44:46Z","timestamp":1757976286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920309237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":62,"alternative-id":["S0014299920309237"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173818","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The bradycardic agent ivabradine decreases conduction velocity in the AV node and in the ventricles in-vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"173818"}}